Walvax Biotechnology Co., Ltd. (SHE:300142)

Walvax Biotechnology Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 29, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Market Capitalization	22,759	17,449	19,320	37,601	64,274	89,423
Market Cap Growth	23.42%	-9.69%	-48.62%	-41.50%	-28.12%	50.25%
Enterprise Value	23,218	17,300	18,563	36,117	62,959	88,584
Last Close Price	14.23	10.77	11.92	23.17	39.60	55.35

Price Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 29, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
PE Ratio	121.26	98.17	135.90	89.66	88.21	209.06
Forward PE	-	50.16	37.75	42.75	54.68	56.13
PS Ratio	10.85	7.22	6.85	9.14	12.64	25.82
PB Ratio	3.10	1.83	1.68	3.30	5.85	8.94
P/TBV Ratio	3.72	2.25	2.31	4.57	8.15	11.16
P/FCF Ratio	1234.95	-	39.71	199.74	582.65	-
P/OCF Ratio	41.52	35.54	18.64	33.16	53.50	126.79

EV Ratios

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 29, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
EV/Sales Ratio	11.07	7.15	6.58	8.78	12.38	25.58
EV/EBITDA Ratio	42.07	35.63	47.89	32.22	44.27	95.49
EV/EBIT Ratio	122.96	165.82	773.04	43.46	53.63	111.82
EV/FCF Ratio	1259.89	-	38.16	191.86	570.72	-

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 29, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Debt / Equity Ratio	0.18	0.04	0.04	0.07	0.04	0.03
Debt / EBITDA Ratio	2.35	0.78	1.19	0.70	0.32	0.34
Debt / FCF Ratio	70.47	-	1.01	4.28	4.19	-
Net Debt / Equity Ratio	0.02	-0.13	-0.28	-0.31	-0.31	-0.31
Net Debt / EBITDA Ratio	0.20	-2.63	-8.44	-3.17	-2.40	-3.37
Net Debt / FCF Ratio	5.94	68.53	-6.72	-18.90	-30.92	7.85
Asset Turnover	0.17	0.18	0.19	0.27	0.35	0.30
Inventory Turnover	0.83	0.95	0.83	0.74	0.72	0.60
Quick Ratio	1.70	2.01	2.63	2.37	2.24	2.07
Current Ratio	2.07	2.35	2.98	2.73	2.55	2.37
Return on Equity (ROE)	1.97%	1.19%	1.52%	4.57%	8.94%	6.74%
Return on Assets (ROA)	0.96%	0.49%	0.10%	3.36%	5.06%	4.25%
Return on Invested Capital (ROIC)	1.93%	0.95%	0.28%	9.20%	14.24%	10.50%
Return on Capital Employed (ROCE)	2.20%	1.00%	0.20%	6.70%	9.90%	7.60%

Yields

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 29, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Earnings Yield	0.83%	1.02%	0.74%	1.11%	1.13%	0.48%
FCF Yield	0.08%	-0.11%	2.52%	0.50%	0.17%	-0.45%
Dividend Yield	1.09%	1.44%	0.08%	0.04%	0.03%	0.05%
Payout Ratio	545.28%	444.39%	28.80%	4.76%	6.88%	19.48%
Buyback Yield / Dilution	-1.20%	-0.05%	0.06%	0.21%	-1.93%	-0.90%
Total Shareholder Return	-0.11%	1.39%	0.15%	0.26%	-1.91%	-0.85%

Data Source: S&P Global Market Intelligence Last updated: Aug 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 4, 2026

Data Sources Report a data error